Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 14Recruiting 10Active not recruiting 5Unknown 2Not yet recruiting 2Terminated 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Neuroblastoma 2Ganglioneuroblastoma 1

Interventions

Carboplatin 126Cisplatin 125Drug Therapy 103Bevacizumab 98Oxaliplatin 97Capecitabine 97Radiotherapy 94Gemcitabine 87Paclitaxel 85tislelizumab 84Cyclophosphamide 82pembrolizumab 77Specimen Handling 77toripalimab 69Injections 63Fluorouracil 62Magnetic Resonance Spectroscopy 61sintilimab 57anlotinib 53130-nm albumin-bound paclitaxel 51Surgical Procedures, Operative 50Docetaxel 49fludarabine 46Pemetrexed 45venetoclax 42Standard of Care 42Leucovorin 42Irinotecan 41lenvatinib 40Biopsy 39

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Interventional × dinutuximab × Clear all
NCT07437963 2026-04-15

Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse

National Cancer Institute (NCI)

Phase 1/2 Not yet recruiting
76 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

NCT07261241 2025-12-03

NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab

New Approaches to Neuroblastoma Therapy Consortium

Phase 2 Not yet recruiting
118 enrolled
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡